Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

INOVIO PHARMACEUTICAL INC (GBMB.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
1.8448+0.0356 (+1.97%)
At close: 09:01PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8092
Open1.8000
Bid1.8618 x N/A
Ask1.8882 x N/A
Day's Range1.7302 - 1.8448
52 Week Range1.3160 - 5.8620
Volume540
Avg. Volume8
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious Disease Programs

    Inovio Pharmaceuticals Inc (NASDAQ: INO) has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue the development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700). Recently, Inovio discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The move follows the initial data analyses from studies conducted by Inovio and funded by CEPI. Dr.

  • American City Business Journals

    Inovio shares fall on discontinuation of development of two more vaccine candidates

    Inovio is discontinuing development of its vaccine product candidates targeting Lassa Fever and Middle East Respiratory Syndrome, or MERS, the latest setback for the Montgomery County biotechnology company. Inovio said it agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to stop work on both experimental products, INO-4500 and INO-4700, following initial analyses of data from studies testing the effectiveness of each.

  • PR Newswire

    INOVIO Provides an Update on Lassa Fever and MERS Programs

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to discontinue development of product candidates targeting Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700), following initial analyses of data from studies condu

Advertisement
Advertisement